----
Current ValuationThe current P/E ratio is -4.76, above the reasonable range, cheaper than 1.15% of the time in the past 1 years, and the industry ranks 43/74, the industry Median --.
-4.76xP/E
$1.27Stock price
$-0.27Earnings per share
-4.76xP/E
Stock price$1.27Earnings per share$-0.27
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -6.11x
- Typical range
- -6.33x–-5.61x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
07142128
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GHUSGuardant Health | -48.24x | 2.97% | $21.87B |
HIMSUSHims & Hers Health | -45.54x | 209.86% | $6.47B |
RDNTUSRadnet | -257.75x | 128.00% | $5.44B |
NEOUSNeogenomics | -41.80x | 64.12% | $2.17B |
WGSUSGeneDx | -19.24x | 359.59% | $2.05B |
AGLUSagilon health | -6.32x | 92.48% | $1.47B |
INNVUSInnovage | -488.36x | 2,301.70% | $1.24B |
OPKUSOpko Health | -14.03x | 25.99% | $1.02B |
LMRIUSLumexa Imaging | -36.59x | 145.51% | $1.01B |
CSTLUSCastle Biosciences | -52.10x | 51.54% | $1.01B |
GMRSUSGMR Solutions | -7.66x | 91.45% | $579.11M |
FLGTUSFulgent Genetics | -6.85x | 42.64% | $578.10M |
AONCUSAmerican Oncology Network | -- | -- | $372.75M |
PREUSPrenetics Global | -7.51x | 15.02% | $353.16M |
BDSXUSBiodesix | -9.12x | 42.77% | $253.12M |
GAMGUSGlobal Asset Management Group, Inc. | -382.76x | -- | $216.04M |
NAKAUSNakamoto | -0.34x | 102.50% | $142.44M |
CORBFUSGlobal Cord Blood Corporation | -- | -- | $127.35M |
AIRSUSAirSculpt Tech | -8.72x | 33.33% | $102.38M |
PARKUSPark Dental Partners | -25.55x | -- | $90.33M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
